Cocrystal Pharma, Inc.
COCPHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The $12.8M market capitalization puts COCP squarely in micro-cap range for its industry. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Market Cap
$12.8M
Beta
1.41
P/E (TTM)
—
P/E (Fwd)
-1.45
EPS (TTM)
$-0.72
EPS (Fwd)
$-0.64
ROE
-154.6%
ROA
-62.4%
Cash
$4.7M
Total Debt
$1.4M
Free CF
-$4.4M
52W Change
-41.9%
Annual Financials
Cash vs Debt
Where COCP stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, COCP finished 15.32% below its 150-day moving average ($1.11) and 14.55% below its 200-day moving average ($1.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COCP overbought or oversold?
At the July 15, 2026 close, COCP's RSI(14) was 26.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cocrystal Pharma, Inc. holds $4.7M in cash against $1.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$4.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -154.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, COCP has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing COCP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.